☰

Neil Osheroff - Publications

Affiliations: 
Vanderbilt University, Nashville, TN 
Area:
Biochemistry
Tree Info Similar researchers PubMed Report error

219 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Deweese JE, Osheroff N. No Time to Relax and Unwind: Exploration of Topoisomerases and a Growing Field of Study. International Journal of Molecular Sciences. 24. PMID 37685888 DOI: 10.3390/ijms241713080  0.646
2023 Dauda SE, Collins JA, Byl JAW, Lu Y, Yalowich JC, Mitton-Fry MJ, Osheroff N. Actions of a Novel Bacterial Topoisomerase Inhibitor against Gyrase and Topoisomerase IV: Enhancement of Double-Stranded DNA Breaks. International Journal of Molecular Sciences. 24. PMID 37569485 DOI: 10.3390/ijms241512107  0.616
2023 Jian JY, Osheroff N. Telling Your Right Hand from Your Left: The Effects of DNA Supercoil Handedness on the Actions of Type II Topoisomerases. International Journal of Molecular Sciences. 24. PMID 37446377 DOI: 10.3390/ijms241311199  0.656
2023 Jian JY, McCarty KD, Byl JAW, Guengerich FP, Neuman KC, Osheroff N. Basis for the discrimination of supercoil handedness during DNA cleavage by human and bacterial type II topoisomerases. Nucleic Acids Research. PMID 36999602 DOI: 10.1093/nar/gkad190  0.885
2023 Byl JAW, Mueller R, Bax B, Basarab GS, Chibale K, Osheroff N. A Series of Spiropyrimidinetriones that Enhances DNA Cleavage Mediated by Gyrase. Acs Infectious Diseases. 9: 706-715. PMID 36802491 DOI: 10.1021/acsinfecdis.3c00012  0.483
2022 Dalvie ED, Stacy JC, Neuman KC, Osheroff N. Recognition of DNA Supercoil Handedness during Catenation Catalyzed by Type II Topoisomerases. Biochemistry. 61: 2148-2158. PMID 36122251 DOI: 10.1021/acs.biochem.2c00370  0.888
2022 Lu Y, Mann CA, Nolan S, Collins JA, Parker E, Papa J, Vibhute S, Jahanbakhsh S, Thwaites M, Hufnagel D, Hazbón MH, Moreno J, Stedman TT, Wittum T, Wozniak DJ, ... Osheroff N, et al. 1,3-Dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Expanding Structural Diversity and the Antibacterial Spectrum. Acs Medicinal Chemistry Letters. 13: 955-963. PMID 35707162 DOI: 10.1021/acsmedchemlett.2c00111  0.32
2022 Van Ravenstein SX, Mehta KP, Kavlashvili T, Byl JAW, Zhao R, Osheroff N, Cortez D, Dewar JM. Topoisomerase II poisons inhibit vertebrate DNA replication through distinct mechanisms. The Embo Journal. e110632. PMID 35578785 DOI: 10.15252/embj.2022110632  0.604
2022 Govender P, Müller R, Singh K, Reddy V, Eyermann CJ, Fienberg S, Ghorpade SR, Koekemoer L, Myrick A, Schnappinger D, Engelhart C, Meshanni J, Byl JAW, Osheroff N, Singh V, et al. Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. Journal of Medicinal Chemistry. 65: 6903-6925. PMID 35500229 DOI: 10.1021/acs.jmedchem.2c00266  0.448
2021 Vann KR, Oviatt AA, Osheroff N. Topoisomerase II Poisons: Converting Essential Enzymes into Molecular Scissors. Biochemistry. 60: 1630-1641. PMID 34008964 DOI: 10.1021/acs.biochem.1c00240  0.641
2021 Collins JA, Osheroff N. 1,2-Naphthoquinone as a Poison of Human Type II Topoisomerases. Chemical Research in Toxicology. PMID 33760604 DOI: 10.1021/acs.chemrestox.0c00492  0.676
2020 Ortega JA, Arencibia JM, Minniti E, Byl JAW, Franco-Ulloa S, Borgogno M, Genna V, Summa M, Bertozzi SM, Bertorelli R, Armirotti A, Minarini A, Sissi C, Osheroff N, De Vivo M. Novel, Potent, and Druglike Tetrahydroquinazoline Inhibitor That Is Highly Selective for Human Topoisomerase II α over β. Journal of Medicinal Chemistry. PMID 33079544 DOI: 10.1021/acs.jmedchem.0c00774  0.411
2020 Gibson EG, Oviatt AA, Osheroff N. Two-Dimensional Gel Electrophoresis to Resolve DNA Topoisomers. Methods in Molecular Biology (Clifton, N.J.). 2119: 15-24. PMID 31989511 DOI: 10.1007/978-1-0716-0323-9_2  0.573
2019 Gibson EG, Oviatt AA, Cacho M, Neuman KC, Chan PF, Osheroff N. Bimodal actions of a naphthyridone/aminopiperidine-based antibacterial that targets gyrase and topoisomerase IV. Biochemistry. PMID 31617352 DOI: 10.1021/Acs.Biochem.9B00805  0.577
2019 Heintzman DR, Campos LV, Byl JAW, Osheroff N, Dewar JM. Topoisomerase II Is Crucial for Fork Convergence during Vertebrate Replication Termination. Cell Reports. 29: 422-436.e5. PMID 31597101 DOI: 10.1016/J.Celrep.2019.08.097  0.542
2019 Kuriappan JA, Osheroff N, De Vivo M. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II. Journal of Chemical Information and Modeling. PMID 31449404 DOI: 10.1021/Acs.Jcim.9B00605  0.615
2019 Dalvie ED, Gopas J, Golan-Goldhirsh A, Osheroff N. 6,6'-Dihydroxythiobinupharidine as a poison of human type II topoisomerases. Bioorganic & Medicinal Chemistry Letters. 29: 1881-1885. PMID 31182315 DOI: 10.1016/J.Bmcl.2019.06.003  0.852
2019 Gibson EG, Bax B, Chan PF, Osheroff N. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase. Acs Infectious Diseases. PMID 30757898 DOI: 10.1021/Acsinfecdis.8B00315  0.588
2018 Jang Y, Son H, Lee SW, Hwang W, Jung SR, Byl JAW, Osheroff N, Lee S. Selection of DNA Cleavage Sites by Topoisomerase II Results from Enzyme-Induced Flexibility of DNA. Cell Chemical Biology. PMID 30713098 DOI: 10.1016/J.Chembiol.2018.12.003  0.674
2018 Oviatt AA, Kuriappan JA, Minniti E, Vann KR, Onuorah P, Minarini A, De Vivo M, Osheroff N. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ. Bioorganic & Medicinal Chemistry Letters. PMID 30006062 DOI: 10.1016/J.Bmcl.2018.07.010  0.58
2018 Gibson EG, Blower TR, Cacho M, Bax BD, Berger JM, Osheroff N. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. Acs Infectious Diseases. PMID 29746087 DOI: 10.1021/Acsinfecdis.8B00035  0.514
2018 Infante Lara L, Fenner S, Ratcliffe S, Isidro-Llobet A, Hann M, Bax B, Osheroff N. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences. Nucleic Acids Research. PMID 29447373 DOI: 10.1093/Nar/Gky072  0.623
2018 Seol Y, Litwin T, Kim L, Nikoobakht L, Osheroff N, Neuman KC. ATP-Dependent Topology Discrimination by Type IIA Topoisomerases: Implications for below Equilibrium Topology Simplification Biophysical Journal. 114: 85a-86a. DOI: 10.1016/J.Bpj.2017.11.510  0.311
2017 Ashley RE, Dittmore A, McPherson SA, Turnbough CL, Neuman KC, Osheroff N. Activities of gyrase and topoisomerase IV on positively supercoiled DNA. Nucleic Acids Research. 45: 9611-9624. PMID 28934496 DOI: 10.1093/Nar/Gkx649  0.643
2017 Ashley RE, Blower TR, Berger JM, Osheroff N. Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. Biochemistry. PMID 28921956 DOI: 10.1021/Acs.Biochem.7B00681  0.683
2017 Minniti E, Byl JAW, Riccardi L, Sissi C, Rosini M, De Vivo M, Minarini A, Osheroff N. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα. Bioorganic & Medicinal Chemistry Letters. PMID 28919339 DOI: 10.1016/J.Bmcl.2017.09.011  0.616
2017 Ashley RE, Lindsey RH, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Interactions between quinolones and Bacillus anthracis gyrase and the basis of drug resistance. Biochemistry. PMID 28708938 DOI: 10.1021/Acs.Biochem.7B00203  0.409
2017 Kristoffersen EL, Givskov A, Jørgensen LA, Jensen PW, W Byl JA, Osheroff N, Andersen AH, Stougaard M, Ho YP, Knudsen BR. Interlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events. Nucleic Acids Research. PMID 28541438 DOI: 10.1093/Nar/Gkx480  0.606
2017 Yu X, Davenport JW, Urtishak KA, Carillo ML, Gosai SJ, Kolaris CP, Byl JA, Rappaport EF, Osheroff N, Gregory BD, Felix CA. Genome-wide TOP2A DNA cleavage is biased towards translocated and highly transcribed loci. Genome Research. PMID 28385713 DOI: 10.1101/Gr.211615.116  0.468
2016 Infante Lara L, Sledge A, Laradji A, Okoro CO, Osheroff N. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα. Bioorganic & Medicinal Chemistry Letters. PMID 27998679 DOI: 10.1016/J.Bmcl.2016.12.011  0.651
2016 Vann KR, Ergün Y, Zencir S, Oncuoglu S, Osheroff N, Topcu Z. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives. Bioorganic & Medicinal Chemistry Letters. 26: 1809-12. PMID 26906637 DOI: 10.1016/J.Bmcl.2016.02.034  0.558
2016 Vann KR, Ekiz G, Zencir S, Bedir E, Topcu Z, Osheroff N. Effects of Secondary Metabolites from the Fungus Septofusidium berolinense on DNA Cleavage Mediated by Human Topoisomerase IIα. Chemical Research in Toxicology. 29: 415-20. PMID 26894873 DOI: 10.1021/Acs.Chemrestox.6B00009  0.674
2016 Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proceedings of the National Academy of Sciences of the United States of America. PMID 26792518 DOI: 10.1073/Pnas.1525055113  0.395
2015 Vann KR, Sedgeman CA, Gopas J, Golan-Goldhirsh A, Osheroff N. Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases. Biochemistry. 54: 4531-41. PMID 26132160 DOI: 10.1021/Acs.Biochem.5B00162  0.658
2015 Aldred KJ, Schwanz HA, Li G, Williamson BH, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions. Biochemistry. 54: 1278-86. PMID 25586498 DOI: 10.1021/Bi501073V  0.476
2014 Dunlap N, Salyard TL, Pathiranage AL, Stubblefield J, Pitts SL, Ashley RE, Osheroff N. Synthesis and evaluation of ether-linked demethylepipodophyllotoxin dimers. Bioorganic & Medicinal Chemistry Letters. 24: 5627-9. PMID 25466187 DOI: 10.1016/J.Bmcl.2014.10.082  0.575
2014 Lindsey RH, Pendleton M, Ashley RE, Mercer SL, Deweese JE, Osheroff N. Catalytic core of human topoisomerase IIα: insights into enzyme-DNA interactions and drug mechanism. Biochemistry. 53: 6595-602. PMID 25280269 DOI: 10.1021/Bi5010816  0.848
2014 Aldred KJ, Breland EJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge. Antimicrobial Agents and Chemotherapy. 58: 7182-7. PMID 25246407 DOI: 10.1128/Aac.03734-14  0.379
2014 Aldred KJ, Breland EJ, Vlčková V, Strub MP, Neuman KC, Kerns RJ, Osheroff N. Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. Biochemistry. 53: 5558-67. PMID 25115926 DOI: 10.1021/Bi500682E  0.458
2014 Smith NA, Byl JA, Mercer SL, Deweese JE, Osheroff N. Etoposide quinone is a covalent poison of human topoisomerase IIβ. Biochemistry. 53: 3229-36. PMID 24766193 DOI: 10.1021/Bi500421Q  0.823
2014 Ketron AC, Osheroff N. Phytochemicals as Anticancer and Chemopreventive Topoisomerase II Poisons. Phytochemistry Reviews : Proceedings of the Phytochemical Society of Europe. 13: 19-35. PMID 24678287 DOI: 10.1007/S11101-013-9291-7  0.637
2014 Ashley RE, Osheroff N. Natural products as topoisomerase II poisons: effects of thymoquinone on DNA cleavage mediated by human topoisomerase IIα. Chemical Research in Toxicology. 27: 787-93. PMID 24650156 DOI: 10.1021/Tx400453V  0.607
2014 Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 53: 1565-74. PMID 24576155 DOI: 10.1021/Bi5000564  0.384
2014 Pendleton M, Lindsey RH, Felix CA, Grimwade D, Osheroff N. Topoisomerase II and leukemia. Annals of the New York Academy of Sciences. 1310: 98-110. PMID 24495080 DOI: 10.1111/Nyas.12358  0.579
2013 Furniss KL, Tsai HJ, Byl JA, Lane AB, Vas AC, Hsu WS, Osheroff N, Clarke DJ. Direct monitoring of the strand passage reaction of DNA topoisomerase II triggers checkpoint activation. Plos Genetics. 9: e1003832. PMID 24098144 DOI: 10.1371/Journal.Pgen.1003832  0.647
2013 Aldred KJ, Schwanz HA, Li G, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. Acs Chemical Biology. 8: 2660-8. PMID 24047414 DOI: 10.1021/Cb400592N  0.406
2013 Timmel MA, Byl JA, Osheroff N. Epimerization of green tea catechins during brewing does not affect the ability to poison human type II topoisomerases. Chemical Research in Toxicology. 26: 622-8. PMID 23514406 DOI: 10.1021/Tx4000667  0.608
2013 Seol Y, Gentry AC, Osheroff N, Neuman KC. Chiral discrimination and writhe-dependent relaxation mechanism of human topoisomerase IIα. The Journal of Biological Chemistry. 288: 13695-703. PMID 23508957 DOI: 10.1074/Jbc.M112.444745  0.856
2013 Aldred KJ, McPherson SA, Turnbough CL, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Research. 41: 4628-39. PMID 23460203 DOI: 10.1093/Nar/Gkt124  0.356
2013 Ketron AC, Gordon ON, Schneider C, Osheroff N. Oxidative metabolites of curcumin poison human type II topoisomerases. Biochemistry. 52: 221-7. PMID 23253398 DOI: 10.1021/Bi3014455  0.574
2012 Schmidt BH, Osheroff N, Berger JM. Structure of a topoisomerase II-DNA-nucleotide complex reveals a new control mechanism for ATPase activity. Nature Structural & Molecular Biology. 19: 1147-54. PMID 23022727 DOI: 10.1038/Nsmb.2388  0.632
2012 Lee S, Jung SR, Heo K, Byl JA, Deweese JE, Osheroff N, Hohng S. DNA cleavage and opening reactions of human topoisomerase IIα are regulated via Mg2+-mediated dynamic bending of gate-DNA. Proceedings of the National Academy of Sciences of the United States of America. 109: 2925-30. PMID 22323612 DOI: 10.1073/Pnas.1115704109  0.854
2012 Ketron AC, Denny WA, Graves DE, Osheroff N. Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions. Biochemistry. 51: 1730-9. PMID 22304499 DOI: 10.1021/Bi201159B  0.599
2012 Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL, Osheroff N. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 51: 370-81. PMID 22126453 DOI: 10.1021/Bi2013905  0.6
2011 Joannides M, Mays AN, Mistry AR, Hasan SK, Reiter A, Wiemels JL, Felix CA, Coco FL, Osheroff N, Solomon E, Grimwade D. Molecular pathogenesis of secondary acute promyelocytic leukemia. Mediterranean Journal of Hematology and Infectious Diseases. 3: e2011045. PMID 22110895 DOI: 10.4084/Mjhid.2011.045  0.416
2011 Jacob DA, Mercer SL, Osheroff N, Deweese JE. Etoposide quinone is a redox-dependent topoisomerase II poison. Biochemistry. 50: 5660-7. PMID 21595477 DOI: 10.1021/Bi200438M  0.86
2011 Pitts SL, Jablonksy MJ, Duca M, Dauzonne D, Monneret C, Arimondo PB, Anklin C, Graves DE, Osheroff N. Contributions of the D-Ring to the activity of etoposide against human topoisomerase IIα: potential interactions with DNA in the ternary enzyme--drug--DNA complex. Biochemistry. 50: 5058-66. PMID 21548574 DOI: 10.1021/Bi200531Q  0.57
2011 Hardin AH, Sarkar SK, Seol Y, Liou GF, Osheroff N, Neuman KC. Direct measurement of DNA bending by type IIA topoisomerases: implications for non-equilibrium topology simplification. Nucleic Acids Research. 39: 5729-43. PMID 21421557 DOI: 10.1093/Nar/Gkr109  0.638
2011 Gentry AC, Pitts SL, Jablonsky MJ, Bailly C, Graves DE, Osheroff N. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage. Biochemistry. 50: 3240-9. PMID 21413765 DOI: 10.1021/Bi200094Z  0.829
2011 Pitts SL, Liou GF, Mitchenall LA, Burgin AB, Maxwell A, Neuman KC, Osheroff N. Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. Nucleic Acids Research. 39: 4808-17. PMID 21300644 DOI: 10.1093/Nar/Gkr018  0.51
2011 Gentry AC, Juul S, Veigaard C, Knudsen BR, Osheroff N. The geometry of DNA supercoils modulates the DNA cleavage activity of human topoisomerase I. Nucleic Acids Research. 39: 1014-22. PMID 20855291 DOI: 10.1093/Nar/Gkq822  0.874
2011 Ketron A, Graves DE, Osheroff N. Abstract 2529: Structure-activity relationship studies of the type II topoisomerase poison amsacrine Cancer Research. 71: 2529-2529. DOI: 10.1158/1538-7445.Am2011-2529  0.401
2011 Lee S, Jung S, Deweese JE, Byl JA, Osheroff N, Hohng S. Single-Molecule Observation of Dynamic Bending and Cleavage of a Gate DNA by Human Topoisomerase IIα Biophysical Journal. 100: 71a. DOI: 10.1016/J.Bpj.2010.12.590  0.826
2010 Turel I, Kljun J, Perdih F, Morozova E, Bakulev V, Kasyanenko N, Byl JA, Osheroff N. First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA. Inorganic Chemistry. 49: 10750-2. PMID 20973588 DOI: 10.1021/Ic101355D  0.49
2010 Deweese JE, Osheroff N. The use of divalent metal ions by type II topoisomerases. Metallomics : Integrated Biometal Science. 2: 450-9. PMID 20703329 DOI: 10.1039/C003759A  0.808
2010 Zechiedrich L, Osheroff N. Topoisomerase IB-DNA interactions: X marks the spot. Structure (London, England : 1993). 18: 661-3. PMID 20541502 DOI: 10.1016/J.Str.2010.05.002  0.525
2010 Schmidt BH, Burgin AB, Deweese JE, Osheroff N, Berger JM. A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases. Nature. 465: 641-4. PMID 20485342 DOI: 10.1038/Nature08974  0.854
2010 De Haro LP, Wray J, Williamson EA, Durant ST, Corwin L, Gentry AC, Osheroff N, Lee SH, Hromas R, Nickoloff JA. Metnase promotes restart and repair of stalled and collapsed replication forks. Nucleic Acids Research. 38: 5681-91. PMID 20457750 DOI: 10.1093/Nar/Gkq339  0.819
2010 Hawtin RE, Stockett DE, Byl JA, McDowell RS, Nguyen T, Arkin MR, Conroy A, Yang W, Osheroff N, Fox JA. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. Plos One. 5: e10186. PMID 20419121 DOI: 10.1371/Journal.Pone.0010186  0.501
2010 Mays AN, Osheroff N, Xiao Y, Wiemels JL, Felix CA, Byl JA, Saravanamuttu K, Peniket A, Corser R, Chang C, Hoyle C, Parker AN, Hasan SK, Lo-Coco F, Solomon E, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood. 115: 326-30. PMID 19884644 DOI: 10.1182/Blood-2009-07-235051  0.402
2010 Osheroff N. GeneticsUntangling the Double Helix: DNA Entanglement and the Action of the DNA Topoisomerases. By James C.Wang. Cold Spring Harbor (New York): Cold Spring Harbor Laboratory Press. $79.00 (hardcover); $45.00 (paper). xi 233 p.; ill.; index. 9780879698638 (hc); 9780879698799 (pb). 2009. The Quarterly Review of Biology. 85: 232-233. DOI: 10.1086/652361  0.45
2010 Seol Y, Gentry AC, Osheroff N, Neuman KC. Single-Molecule Study of Human Topoisomerase II Biophysical Journal. 98: 660a. DOI: 10.1016/J.Bpj.2009.12.3624  0.878
2010 Hardin AH, Liou GF, Osheroff N, Neuman KC. Determining the Role DNA of Bending in Topology Simplification by Type II Topoisomerases Biophysical Journal. 98: 660a. DOI: 10.1016/J.Bpj.2009.12.3623  0.666
2009 Bandele OJ, Osheroff N. Cleavage of plasmid DNA by eukaryotic topoisomerase II. Methods in Molecular Biology (Clifton, N.J.). 582: 39-47. PMID 19763940 DOI: 10.1007/978-1-60761-340-4_4  0.889
2009 Deweese JE, Guengerich FP, Burgin AB, Osheroff N. Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha. Biochemistry. 48: 8940-7. PMID 19697956 DOI: 10.1021/Bi900875C  0.757
2009 Deweese JE, Burch AM, Burgin AB, Osheroff N. Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases. Biochemistry. 48: 1862-9. PMID 19222228 DOI: 10.1021/Bi8023256  0.794
2009 Deweese JE, Osheroff N. Coordinating the two protomer active sites of human topoisomerase IIalpha: nicks as topoisomerase II poisons. Biochemistry. 48: 1439-41. PMID 19166355 DOI: 10.1021/Bi8021679  0.862
2009 Deweese JE, Osheroff N. The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing. Nucleic Acids Research. 37: 738-48. PMID 19042970 DOI: 10.1093/Nar/Gkn937  0.874
2008 Deweese JE, Osheroff MA, Osheroff N. DNA Topology and Topoisomerases: Teaching a "Knotty" Subject. Biochemistry and Molecular Biology Education : a Bimonthly Publication of the International Union of Biochemistry and Molecular Biology. 37: 2-10. PMID 19225573 DOI: 10.1002/Bmb.20244  0.837
2008 McClendon AK, Gentry AC, Dickey JS, Brinch M, Bendsen S, Andersen AH, Osheroff N. Bimodal recognition of DNA geometry by human topoisomerase II alpha: preferential relaxation of positively supercoiled DNA requires elements in the C-terminal domain. Biochemistry. 47: 13169-78. PMID 19053267 DOI: 10.1021/Bi800453H  0.868
2008 Bandele OJ, Osheroff N. The efficacy of topoisomerase II-targeted anticancer agents reflects the persistence of drug-induced cleavage complexes in cells. Biochemistry. 47: 11900-8. PMID 18922022 DOI: 10.1021/Bi800981J  0.827
2008 Deweese JE, Burgin AB, Osheroff N. Human topoisomerase IIalpha uses a two-metal-ion mechanism for DNA cleavage. Nucleic Acids Research. 36: 4883-93. PMID 18653531 DOI: 10.1093/Nar/Gkn466  0.796
2008 Hasan SK, Mays AN, Ottone T, Ledda A, La Nasa G, Cattaneo C, Borlenghi E, Melillo L, Montefusco E, Cervera J, Stephen C, Satchi G, Lennard A, Libura M, Byl JA, ... Osheroff N, et al. Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood. 112: 3383-90. PMID 18650449 DOI: 10.1182/Blood-2007-10-115600  0.338
2008 Bandele OJ, Clawson SJ, Osheroff N. Dietary polyphenols as topoisomerase II poisons: B ring and C ring substituents determine the mechanism of enzyme-mediated DNA cleavage enhancement. Chemical Research in Toxicology. 21: 1253-60. PMID 18461976 DOI: 10.1021/Tx8000785  0.826
2008 Bender RP, Jablonksy MJ, Shadid M, Romaine I, Dunlap N, Anklin C, Graves DE, Osheroff N. Substituents on etoposide that interact with human topoisomerase IIalpha in the binary enzyme-drug complex: contributions to etoposide binding and activity. Biochemistry. 47: 4501-9. PMID 18355043 DOI: 10.1021/Bi702019Z  0.811
2008 Deweese JE, Burgin AB, Osheroff N. Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha. Biochemistry. 47: 4129-40. PMID 18318502 DOI: 10.1021/Bi702194X  0.867
2008 Bandele OJ, Osheroff N. (-)-Epigallocatechin gallate, a major constituent of green tea, poisons human type II topoisomerases. Chemical Research in Toxicology. 21: 936-43. PMID 18293940 DOI: 10.1021/Tx700434V  0.885
2008 Robinson BW, Cheung NK, Kolaris CP, Jhanwar SC, Choi JK, Osheroff N, Felix CA. Prospective tracing of MLL-FRYL clone with low MEIS1 expression from emergence during neuroblastoma treatment to diagnosis of myelodysplastic syndrome. Blood. 111: 3802-12. PMID 18195096 DOI: 10.1182/Blood-2007-07-096065  0.35
2007 Frøhlich RF, Veigaard C, Andersen FF, McClendon AK, Gentry AC, Andersen AH, Osheroff N, Stevnsner T, Knudsen BR. Tryptophane-205 of human topoisomerase I is essential for camptothecin inhibition of negative but not positive supercoil removal. Nucleic Acids Research. 35: 6170-80. PMID 17827209 DOI: 10.1093/Nar/Gkm669  0.842
2007 McClendon AK, Osheroff N. DNA topoisomerase II, genotoxicity, and cancer. Mutation Research. 623: 83-97. PMID 17681352 DOI: 10.1016/J.Mrfmmm.2007.06.009  0.877
2007 Wilstermann AM, Bender RP, Godfrey M, Choi S, Anklin C, Berkowitz DB, Osheroff N, Graves DE. Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme. Biochemistry. 46: 8217-25. PMID 17580961 DOI: 10.1021/Bi700272U  0.842
2007 Bender RP, Osheroff N. Mutation of cysteine residue 455 to alanine in human topoisomerase IIalpha confers hypersensitivity to quinones: enhancing DNA scission by closing the N-terminal protein gate. Chemical Research in Toxicology. 20: 975-81. PMID 17516663 DOI: 10.1021/Tx700062T  0.873
2007 Bandele OJ, Osheroff N. Bioflavonoids as poisons of human topoisomerase II alpha and II beta. Biochemistry. 46: 6097-108. PMID 17458941 DOI: 10.1021/Bi7000664  0.866
2007 Bender RP, Ham AJ, Osheroff N. Quinone-induced enhancement of DNA cleavage by human topoisomerase IIalpha: adduction of cysteine residues 392 and 405. Biochemistry. 46: 2856-64. PMID 17298034 DOI: 10.1021/Bi062017L  0.85
2006 Osheroff N. Unraveling the structure of the variola topoisomerase IB-DNA complex: a possible new twist on smallpox therapy. Molecular Interventions. 6: 245-8. PMID 17035663 DOI: 10.1124/Mi.6.5.4  0.417
2006 McClendon AK, Dickey JS, Osheroff N. Ability of viral topoisomerase II to discern the handedness of supercoiled DNA: bimodal recognition of DNA geometry by type II enzymes. Biochemistry. 45: 11674-80. PMID 16981727 DOI: 10.1021/Bi0520838  0.887
2006 Bender RP, Lehmler HJ, Robertson LW, Ludewig G, Osheroff N. Polychlorinated biphenyl quinone metabolites poison human topoisomerase IIalpha: altering enzyme function by blocking the N-terminal protein gate. Biochemistry. 45: 10140-52. PMID 16906772 DOI: 10.1021/Bi0524666  0.801
2006 Felix CA, Kolaris CP, Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. Dna Repair. 5: 1093-108. PMID 16857431 DOI: 10.1016/J.Dnarep.2006.05.031  0.491
2006 Duca M, Guianvarc'h D, Oussedik K, Halby L, Garbesi A, Dauzonne D, Monneret C, Osheroff N, Giovannangeli C, Arimondo PB. Molecular basis of the targeting of topoisomerase II-mediated DNA cleavage by VP16 derivatives conjugated to triplex-forming oligonucleotides. Nucleic Acids Research. 34: 1900-11. PMID 16598074 DOI: 10.1093/Nar/Gkl126  0.641
2006 McClendon AK, Osheroff N. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs. Biochemistry. 45: 3040-50. PMID 16503659 DOI: 10.1021/Bi051987Q  0.871
2005 Dickey JS, Van Etten JL, Osheroff N. DNA methylation impacts the cleavage activity of Chlorella virus topoisomerase II. Biochemistry. 44: 15378-86. PMID 16285742 DOI: 10.1021/Bi051334+  0.838
2005 McClendon AK, Rodriguez AC, Osheroff N. Human topoisomerase IIalpha rapidly relaxes positively supercoiled DNA: implications for enzyme action ahead of replication forks. The Journal of Biological Chemistry. 280: 39337-45. PMID 16188892 DOI: 10.1074/Jbc.M503320200  0.878
2005 Dickey JS, Osheroff N. Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme. Biochemistry. 44: 11546-54. PMID 16114891 DOI: 10.1021/Bi050811L  0.824
2005 Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Current Medicinal Chemistry. Anti-Cancer Agents. 5: 363-72. PMID 16101488 DOI: 10.2174/1568011054222364  0.683
2005 Lindsey RH, Bender RP, Osheroff N. Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites. Chemico-Biological Interactions. 153: 197-205. PMID 15935817 DOI: 10.1016/J.Cbi.2005.03.035  0.882
2005 Lindsey RH, Bender RP, Osheroff N. Effects of benzene metabolites on DNA cleavage mediated by human topoisomerase II alpha: 1,4-hydroquinone is a topoisomerase II poison. Chemical Research in Toxicology. 18: 761-70. PMID 15833037 DOI: 10.1021/Tx049659Z  0.84
2005 Mistry AR, Felix CA, Whitmarsh RJ, Mason A, Reiter A, Cassinat B, Parry A, Walz C, Wiemels JL, Segal MR, Adès L, Blair IA, Osheroff N, Peniket AJ, Lafage-Pochitaloff M, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. The New England Journal of Medicine. 352: 1529-38. PMID 15829534 DOI: 10.1056/Nejmoa042715  0.458
2005 Vélez-Cruz R, Riggins JN, Daniels JS, Cai H, Guengerich FP, Marnett LJ, Osheroff N. Exocyclic DNA lesions stimulate DNA cleavage mediated by human topoisomerase IIα in vitro and in cultured cells Biochemistry. 44: 3972-3981. PMID 15751973 DOI: 10.1021/Bi0478289  0.674
2005 Dickey JS, Choi TJ, Van Etten JL, Osheroff N. Chlorella virus Marburg topoisomerase II: high DNA cleavage activity as a characteristic of Chlorella virus type II enzymes. Biochemistry. 44: 3899-908. PMID 15751965 DOI: 10.1021/Bi047777F  0.852
2005 Baldwin EL, Berger AC, Corbett AH, Osheroff N. Mms22p protects Saccharomyces cerevisiae from DNA damage induced by topoisomerase II. Nucleic Acids Research. 33: 1021-30. PMID 15718301 DOI: 10.1093/Nar/Gki246  0.667
2005 Kolaris CP, Slater DJ, Perl AS, Rappaport EF, Osheroff N, Felix CA. DNA Topoisomerase II Poisons and the Etiology of Acute Leukemia in Infants. Blood. 106: 2850-2850. DOI: 10.1182/Blood.V106.11.2850.2850  0.504
2004 Bromberg KD, Vélez-Cruz R, Burgin AB, Osheroff N. DNA ligation catalyzed by human topoisomerase II alpha. Biochemistry. 43: 13416-23. PMID 15491148 DOI: 10.1021/Bi049420H  0.89
2004 Lindsey RH, Bromberg KD, Felix CA, Osheroff N. 1,4-Benzoquinone is a topoisomerase II poison. Biochemistry. 43: 7563-74. PMID 15182198 DOI: 10.1021/Bi049756R  0.717
2004 Bender RP, Lindsey RH, Burden DA, Osheroff N. N-acetyl-p-benzoquinone imine, the toxic metabolite of acetaminophen, is a topoisomerase II poison. Biochemistry. 43: 3731-9. PMID 15035644 DOI: 10.1021/Bi036107R  0.864
2004 Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA. Biological characterization of MLN944: a potent DNA binding agent. Molecular Cancer Therapeutics. 3: 47-58. PMID 14749475  0.826
2004 Baldwin EL, Byl JA, Osheroff N. Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry. 43: 728-35. PMID 14730977 DOI: 10.1021/Bi035472F  0.698
2004 Kolaris CP, Liu M, Foote K, Aplan PD, Ahuja HG, Osheroff N, Felix CA. NUP98 Translocation Breakpoints in Treatment-Related MDS Are Drug-Stimulated DNA Topoisomerase II Cleavage Sites. Blood. 104: 1970-1970. DOI: 10.1182/Blood.V104.11.1970.1970  0.483
2003 Whitmarsh RJ, Saginario C, Zhuo Y, Hilgenfeld E, Rappaport EF, Megonigal MD, Carroll M, Liu M, Osheroff N, Cheung NKV, Slater DJ, Ried T, Knutsen T, Blair IA, Felix CA. Reciprocal DNA topoisomerase II cleavage events at 5′-TATTA-3′ sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing Oncogene. 22: 8448-8459. PMID 14627986 DOI: 10.1038/Sj.Onc.1207052  0.678
2003 Mårtensson S, Nygren J, Osheroff N, Hammarsten O. Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiation Research. 160: 291-301. PMID 12926987 DOI: 10.1667/0033-7587(2003)160[0291:Aotdpk]2.0.Co;2  0.652
2003 Sabourin M, Nitiss JL, Nitiss KC, Tatebayashi K, Ikeda H, Osheroff N. Yeast recombination pathways triggered by topoisomerase II-mediated DNA breaks. Nucleic Acids Research. 31: 4373-84. PMID 12888496 DOI: 10.1093/Nar/Gkg497  0.818
2003 Bromberg KD, Burgin AB, Osheroff N. Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage. Biochemistry. 42: 3393-8. PMID 12653542 DOI: 10.1021/Bi027383T  0.708
2003 Wilstermann AM, Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Current Topics in Medicinal Chemistry. 3: 321-38. PMID 12570766 DOI: 10.2174/1568026033452519  0.894
2003 Bromberg KD, Burgin AB, Osheroff N. A two-drug model for etoposide action against human topoisomerase IIalpha. The Journal of Biological Chemistry. 278: 7406-12. PMID 12473657 DOI: 10.1074/Jbc.M212056200  0.666
2002 Fortune JM, Dickey JS, Lavrukhin OV, Van Etten JL, Lloyd RS, Osheroff N. Site-specific DNA cleavage by Chlorella virus topoisomerase II. Biochemistry. 41: 11761-9. PMID 12269818 DOI: 10.1021/Bi025802G  0.857
2002 Slater DJ, Hilgenfeld E, Rappaport EF, Shah N, Meek RG, Williams WR, Lovett BD, Osheroff N, Autar RS, Ried T, Felix CA. MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site. Oncogene. 21: 4706-14. PMID 12096348 DOI: 10.1038/Sj.Onc.1205572  0.32
2002 Bromberg KD, Hendricks C, Burgin AB, Osheroff N. Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism. The Journal of Biological Chemistry. 277: 31201-6. PMID 12050172 DOI: 10.1074/Jbc.M204741200  0.708
2001 Wilstermann AM, Osheroff N. Base excision repair intermediates as topoisomerase II poisons. The Journal of Biological Chemistry. 276: 46290-6. PMID 11591703 DOI: 10.1074/Jbc.M105733200  0.879
2001 Lovett BD, Lo Nigro L, Rappaport EF, Blair IA, Osheroff N, Zheng N, Megonigal MD, Williams WR, Nowell PC, Felix CA. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. Proceedings of the National Academy of Sciences of the United States of America. 98: 9802-7. PMID 11493704 DOI: 10.1073/Pnas.171309898  0.666
2001 Bromberg KD, Osheroff N. DNA cleavage and religation by human topoisomerase IIα at high temperature Biochemistry. 40: 8410-8418. PMID 11444988 DOI: 10.1021/Bi010681Q  0.623
2001 Wilstermann AM, Osheroff N. Positioning the 3'-DNA terminus for topoisomerase II-mediated religation. The Journal of Biological Chemistry. 276: 17727-31. PMID 11359787 DOI: 10.1074/Jbc.M100197200  0.89
2001 Fortune JM, Lavrukhin OV, Gurnon JR, Van Etten JL, Lloyd RS, Osheroff N. Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity. The Journal of Biological Chemistry. 276: 24401-8. PMID 11323425 DOI: 10.1074/Jbc.M101693200  0.654
2001 Anderson VE, Osheroff N. Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde. Current Pharmaceutical Design. 7: 337-53. PMID 11254893 DOI: 10.2174/1381612013398013  0.534
2001 Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal MD, Rappaport EF, Rebbeck TR, Osheroff N, Pommier YG, Felix CA. Etoposide metabolites enhance DNA topoisomerase II cleavage near leukemia-associated MLL translocation breakpoints. Biochemistry. 40: 1159-70. PMID 11170441 DOI: 10.1021/Bi002361X  0.637
2001 Byl JAW, Cline SD, Utsugi T, Kobunai T, Yamada Y, Osheroff N. DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action Biochemistry. 40: 712-718. PMID 11170388 DOI: 10.1021/Bi0021838  0.616
2001 Burden DA, Froelich-Ammon SJ, Osheroff N. Topoisomerase II-mediated cleavage of plasmid DNA Methods in Molecular Biology (Clifton, N.J.). 95: 283-289. PMID 11089240 DOI: 10.1385/1-59259-057-8:283  0.682
2001 Fortune JM, Osheroff N. Topoisomerase II-catalyzed relaxation and catenation of plasmid DNA. Methods in Molecular Biology (Clifton, N.J.). 95: 275-81. PMID 11089239 DOI: 10.1385/1-59259-057-8:275  0.68
2001 Kingma PS, Fortune JM, Osheroff N. Topoisomerase II-catalyzed ATP hydrolysis as monitored by thin-layer chromatography. Methods in Molecular Biology (Clifton, N.J.). 95: 51-6. PMID 11089218 DOI: 10.1385/1-59259-057-8:51  0.365
2000 Durrieu F, Samejima K, Fortune JM, Kandels-Lewis S, Osheroff N, Earnshaw WC. DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin condensation during apoptotic execution. Current Biology : Cb. 10: 923-6. PMID 10959840 DOI: 10.1016/S0960-9822(00)00620-5  0.398
2000 Bjergbaek L, Kingma P, Nielsen IS, Wang Y, Westergaard O, Osheroff N, Andersen AH. Communication between the ATPase and cleavage/religation domains of human topoisomerase IIα Journal of Biological Chemistry. 275: 13041-13048. PMID 10777608 DOI: 10.1074/Jbc.275.17.13041  0.492
2000 Sabourin M, Osheroff N. Sensitivity of human type II topoisomerases to DNA damage: stimulation of enzyme-mediated DNA cleavage by abasic, oxidized and alkylated lesions. Nucleic Acids Research. 28: 1947-54. PMID 10756196 DOI: 10.1093/Nar/28.9.1947  0.817
2000 Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry. 39: 2726-32. PMID 10704224 DOI: 10.1021/Bi992302N  0.664
2000 Lavrukhin OV, Fortune JM, Wood TG, Burbank DE, Van Etten JL, Osheroff N, Lloyd RS. Topoisomerase II from Chlorella virus PBCV-1. Characterization of the smallest known type II topoisomerase. The Journal of Biological Chemistry. 275: 6915-21. PMID 10702252 DOI: 10.1074/Jbc.275.10.6915  0.672
2000 Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology. 64: 221-53. PMID 10697411 DOI: 10.1016/S0079-6603(00)64006-0  0.669
2000 Jensen LH, Nitiss KC, Rose A, Dong J, Zhou J, Hu T, Osheroff N, Jensen PB, Sehested M, Nitiss JL. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines Journal of Biological Chemistry. 275: 2137-2146. PMID 10636919 DOI: 10.1074/Jbc.275.3.2137  0.601
1999 Froelich-Ammon SJ, Kingma PS, Osheroff N. Purification of DNA topoisomerase II from Drosophila melanogaster Methods in Molecular Biology (Clifton, N.J.). 94: 199-212. PMID 12844876 DOI: 10.1385/1-59259-259-7:199  0.67
1999 Bjornsti MA, Osheroff N. Introduction to DNA topoisomerases Methods in Molecular Biology (Clifton, N.J.). 94: 1-8. PMID 12844856 DOI: 10.1385/1-59259-259-7:1  0.615
1999 Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries. The Journal of Biological Chemistry. 274: 35927-32. PMID 10585479 DOI: 10.1074/Jbc.274.50.35927  0.655
1999 Fortune JM, Velea L, Graves DE, Utsugi T, Yamada Y, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition. Biochemistry. 38: 15580-6. PMID 10569942 DOI: 10.1021/Bi991792G  0.708
1999 Byl JA, Fortune JM, Burden DA, Nitiss JL, Utsugi T, Yamada Y, Osheroff N. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement. Biochemistry. 38: 15573-9. PMID 10569941 DOI: 10.1021/Bi991791O  0.653
1999 Cline SD, Jones WR, Stone MP, Osheroff N. DNA abasic lesions in a different light: solution structure of an endogenous topoisomerase II poison. Biochemistry. 38: 15500-7. PMID 10569932 DOI: 10.1021/Bi991750S  0.627
1999 Cline SD, Osheroff N. Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes Journal of Biological Chemistry. 274: 29740-29743. PMID 10514448 DOI: 10.1074/Jbc.274.42.29740  0.676
1999 Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, Garcia M, Osheroff N, Ahn NG. Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Molecular and Cellular Biology. 19: 3551-60. PMID 10207078 DOI: 10.1128/Mcb.19.5.3551  0.348
1999 Kingma PS, Burden DA, Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: Decreased affinity as a mechanism of drug resistance Biochemistry. 38: 3457-3461. PMID 10090731 DOI: 10.1021/bi982855i  0.489
1999 Burden DA, Osheroff N. In vitro evolution of preferred topoisomerase II DNA cleavage sites Journal of Biological Chemistry. 274: 5227-5235. PMID 9988773 DOI: 10.1074/Jbc.274.8.5227  0.692
1998 Osheroff N. DNA topoisomerases Biochimica Et Biophysica Acta. 1400: 1-2. PMID 9867354 DOI: 10.1016/S0167-4781(98)00123-7  0.54
1998 Sabourin M, Byl JA, Hannah SE, Nitiss JL, Osheroff N. A mutant yeast topoisomerase II (top2G437S) with differential sensitivity to anticancer drugs in the presence and absence of ATP. The Journal of Biological Chemistry. 273: 29086-92. PMID 9786915 DOI: 10.1074/Jbc.273.44.29086  0.669
1998 Kingma PS, Osheroff N. The response of eukaryotic topoisomerases to DNA damage Biochimica Et Biophysica Acta - Gene Structure and Expression. 1400: 223-232. PMID 9748592 DOI: 10.1016/S0167-4781(98)00138-9  0.669
1998 Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochimica Et Biophysica Acta - Gene Structure and Expression. 1400: 139-154. PMID 9748545 DOI: 10.1016/S0167-4781(98)00132-8  0.616
1998 Kingma PS, Osheroff N. Topoisomerase II-mediated DNA cleavage and religation in the absence of base pairing. A basic lesions as a tool to dissect enzyme mechanism Journal of Biological Chemistry. 273: 17999-18002. PMID 9660751 DOI: 10.1074/Jbc.273.29.17999  0.696
1998 Anderson VE, Gootz TD, Osheroff N. Topoisomerase IV catalysis and the mechanism of quinolone action Journal of Biological Chemistry. 273: 17879-17885. PMID 9651393 DOI: 10.1074/Jbc.273.28.17879  0.698
1998 Fortune JM, Osheroff N. Merbarone inhibits the catalytic activity of human topoisomerase IIalpha by blocking DNA cleavage. The Journal of Biological Chemistry. 273: 17643-50. PMID 9651360 DOI: 10.1074/Jbc.273.28.17643  0.684
1998 Nitiss JL, Zhou J, Rose A, Hsiung Y, Gale KC, Osheroff N. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II. Biochemistry. 37: 3078-85. PMID 9485461 DOI: 10.1021/Bi9723257  0.578
1997 Marx G, Zhou H, Graves DE, Osheroff N. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage Biochemistry. 36: 15884-15891. PMID 9398321 DOI: 10.1021/Bi971858C  0.731
1997 Cline SD, Macdonald TL, Osheroff N. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine. Biochemistry. 36: 13095-101. PMID 9335572 DOI: 10.1021/Bi971770Z  0.558
1997 Kingma PS, Greider CA, Osheroff N. Spontaneous DNA lesions poison human topoisomerase IIalpha and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints. Biochemistry. 36: 5934-9. PMID 9166762 DOI: 10.1021/Bi970507V  0.632
1997 Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs Biochemistry. 36: 2919-2924. PMID 9062121 DOI: 10.1021/bi962488f  0.753
1997 Kingma PS, Osheroff N. Spontaneous DNA damage stimulates topoisomerase II-mediated DNA cleavage Journal of Biological Chemistry. 272: 7488-7493. PMID 9054451 DOI: 10.1074/Jbc.272.11.7488  0.668
1997 Kingma PS, Osheroff N. Apurinic sites are position-specific topoisomerase II poisons Journal of Biological Chemistry. 272: 1148-1155. PMID 8995415 DOI: 10.1074/Jbc.272.2.1148  0.681
1997 Kingma PS, Osheroff N. Spontaneous DNA lesions are topoisomerase II poisons Faseb Journal. 11.  0.603
1997 Fortune JM, Osheroff N. Topoisomerase II-DNA binding interactions Faseb Journal. 11.  0.513
1996 Burden DA, Kingma PS, Froelich-Ammon SJ, Bjornsti MA, Patchan MW, Thompson RB, Osheroff N. Topoisomerase II-etoposide interactions direct the formation of drug- induced enzyme-DNA cleavage complexes Journal of Biological Chemistry. 271: 29238-29244. PMID 8910583 DOI: 10.1074/Jbc.271.46.29238  0.666
1996 Kingma PS, Osheroff N. Site-specific apurinic sites enhance topoisomerase II-mediated double-stranded dna cleavage Faseb Journal. 10.  0.617
1995 Elsea SH, Hsiung Y, Nitiss JL, Osheroff N. A yeast type II topoisomerase selected for resistance to quinolones: Mutation of histidine 1012 to tyrosine confers resistance to nonintercalative drugs but hypersensitivity to ellipticine Journal of Biological Chemistry. 270: 1913-1920. PMID 7829529 DOI: 10.1074/Jbc.270.4.1913  0.717
1995 Froelich-Ammon SJ, Patchan MW, Osheroff N, Thompson RB. Topoisomerase II binds to ellipticine in the absence or presence of DNA: Chaeacterization of enzyme · drug interactions by fluorescence spectroscopy Journal of Biological Chemistry. 270: 14998-15004. PMID 7797481 DOI: 10.1074/Jbc.270.25.14998  0.676
1995 Kingma PS, Corbett AH, Burcham PC, Marnett LJ, Osheroff N. Abasic sites stimulate double-stranded DNA cleavage mediated by topoisomerase II. DNA lesions as endogenous topoisomerase II poisons Journal of Biological Chemistry. 270: 21441-21444. PMID 7665552 DOI: 10.1074/Jbc.270.37.21441  0.684
1995 Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism Journal of Biological Chemistry. 270: 21429-21432. PMID 7665550 DOI: 10.1074/Jbc.270.37.21429  0.393
1995 Hsiung Y, Elsea SH, Osheroff N, Nitiss JL. A mutation in yeast TOP2 homologous to a quinolone-resistant mutation in bacteria: Mutation of the amino acid homologous to Ser83 of Escherichia coli gyrA alters sensitivity to eukaryotic topoisomerase inhibitors Journal of Biological Chemistry. 270: 20359-20364. PMID 7657608 DOI: 10.1074/Jbc.270.35.20359  0.7
1995 Froelich-Ammon SJ, Burden DA, Patchan MW, Elsea SH, Thompson RB, Osheroff N. Increased drug affinity as the mechanistic basis for drug hypersensitivity of a mutant type II topoisomerase Journal of Biological Chemistry. 270: 28018-28021. PMID 7499285 DOI: 10.1074/jbc.270.47.28018  0.668
1994 Osheroff N, Corbett AH, Robinson MJ. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Advances in Pharmacology (San Diego, Calif.). 29: 105-26. PMID 8996604 DOI: 10.1016/S1054-3589(08)61134-5  0.655
1994 Froelich-Ammon SJ, Gale KC, Osheroff N. Site-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage. The Journal of Biological Chemistry. 269: 7719-25. PMID 8125998  0.609
1994 Osheroff N, Corbett AH, Elsea SH, Westergaard M. Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes Cancer Chemotherapy and Pharmacology. 34. PMID 8070023 DOI: 10.1007/Bf00684859  0.745
1993 Kroeger PE, Osheroff N, Rowe TC. Analysis of topoisomerase II-mediated DNA cleavage in the 5'-region of the Drosophila hsp70 gene. Identification of a novel half-site DNA substrate for topoisomerase II cleavage Journal of Biological Chemistry. 268: 16449-16457. PMID 8393863  0.587
1993 Corbett AH, Hong D, Osheroff N. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme Journal of Biological Chemistry. 268: 14394-14398. PMID 8390992  0.598
1993 Froelich-Ammon SJ, McGuirk PR, Gootz TD, Jefson MR, Osheroff N. Novel 1-8-bridged chiral quinolones with activity against topoisomerase II: Stereospecificity of the eukaryotic enzyme Antimicrobial Agents and Chemotherapy. 37: 646-651. PMID 8388196 DOI: 10.1128/Aac.37.4.646  0.626
1993 Robinson MJ, Corbett AH, Osheroff N. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II. Biochemistry. 32: 3638-43. PMID 8385484 DOI: 10.1021/Bi00065A016  0.643
1993 Corbett AH, Fernald AW, Osheroff N. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of ATP hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry. 32: 2090-7. PMID 8383533 DOI: 10.1021/Bi00059A029  0.484
1993 Corbett AH, Osheroff N. When good enzymes go bad: Conversion of topoisomerase II to a cellular toxin by antineoplastic drugs Chemical Research in Toxicology. 6: 585-597. PMID 8292734 DOI: 10.1021/Tx00035A001  0.384
1993 Elsea SH, McGuirk PR, Gootz TD, Moynihan M, Osheroff N. Drug features that contribute to the activity of quinolones against mammalian topoisomerase II and cultured cells: correlation between enhancement of enzyme-mediated DNA cleavage in vitro and cytotoxic potential. Antimicrobial Agents and Chemotherapy. 37: 2179-86. PMID 8257142 DOI: 10.1128/Aac.37.10.2179  0.782
1993 Corbett AH, Guerry P, Pflieger P, Osheroff N. A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: A novel class of topoisomerase II-targeted drugs with cytotoxic potential Antimicrobial Agents and Chemotherapy. 37: 2599-2605. PMID 8109923 DOI: 10.1128/Aac.37.12.2599  0.632
1992 Corbett AH, DeVore RF, Osheroff N. Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis Journal of Biological Chemistry. 267: 20513-20518. PMID 1328202  0.488
1992 Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N. Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group. Antimicrobial Agents and Chemotherapy. 36: 751-6. PMID 1323952 DOI: 10.1128/Aac.36.4.751  0.63
1992 Elsea SH, Osheroff N, Nitiss JL. Cytotoxicity of quinolones toward eukaryotic cells: Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast Journal of Biological Chemistry. 267: 13150-13153. PMID 1320012  0.425
1992 Gale KC, Osheroff N. Intrinsic intermolecular DNA ligation activity of eukaryotic topoisomerase II. Potential roles in recombination. The Journal of Biological Chemistry. 267: 12090-7. PMID 1318309  0.648
1992 DeVore RF, Corbett AH, Osheroff N. Phosphorylation of Topoisomerase II by Casein Kinase II and Protein Kinase C: Effects on Enzyme-mediated DNA Cleavage/Religation and Sensitivity to the Antineoplastic Drugs Etoposide and 4'-(9-Acridinylamino)methane-sulfonm- anisidide Cancer Research. 52: 2156-2161. PMID 1313738  0.491
1992 Corbett AH, Zechiedrich EL, Osheroff N. A role for the passage helix in the DNA cleavage reaction of eukaryotic topoisomerase II. A two-site model for enzyme-mediated DNA cleavage Journal of Biological Chemistry. 267: 683-686. PMID 1309770  0.632
1991 Robinson MJ, Osheroff N. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II. Biochemistry. 30: 1807-13. PMID 1847075 DOI: 10.1021/Bi00221A012  0.714
1991 Corbett AH, Zechiedrich EL, Lloyd RS, Osheroff N. Inhibition of eukaryotic topoisomerase II by ultraviolet-induced cyclobutane pyrimidine dimers Journal of Biological Chemistry. 266: 19666-19671. PMID 1655791  0.646
1991 Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 13: 269-73. PMID 1654050 DOI: 10.1002/Bies.950130603  0.619
1991 Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Moynihan M, Sutcliffe JA, Osheroff N. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. The Journal of Biological Chemistry. 266: 14585-92. PMID 1650363  0.591
1991 Osheroff N. DNA Topology and its Biological Effects. Based on a Cold Spring Harbor Meeting Held in 1986.Nicholas R. Cozzarelli , James C. Wang The Quarterly Review of Biology. 66: 332-332. DOI: 10.1086/417261  0.344
1990 Ackerman P, Glover CV, Osheroff N. Stimulation of casein kinase II by epidermal growth factor: relationship between the physiological activity of the kinase and the phosphorylation state of its beta subunit. Proceedings of the National Academy of Sciences of the United States of America. 87: 821-5. PMID 2300566 DOI: 10.1073/Pnas.87.2.821  0.303
1990 Gale KC, Osheroff N. Uncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate. Biochemistry. 29: 9538-45. PMID 2176849 DOI: 10.1021/Bi00493A007  0.689
1990 Lynn Zechiedrich E, Osheroff N. Eukaryotic topoisomerases recognize nucleic acid topology by preferentially interacting with DNA crossovers Embo Journal. 9: 4555-4562. PMID 2176156 DOI: 10.1002/J.1460-2075.1990.Tb07908.X  0.675
1990 Robinson MJ, Osheroff N. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide. Biochemistry. 29: 2511-5. PMID 2159323 DOI: 10.1021/Bi00462A012  0.703
1989 Andersen AH, Christiansen K, Zechiedrich EL, Jensen PS, Osheroff N, Westergaard O. Strand specificity of the topoisomerase II mediated double-stranded DNA cleavage reaction Biochemistry. 28: 6237-6244. PMID 2551368 DOI: 10.1021/Bi00441A015  0.694
1989 Zechiedrich EL, Christiansen K, Andersen AH, Westergaard O, Osheroff N. Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: Evidence for a nicked DNA intermediate Biochemistry. 28: 6229-6236. PMID 2551367 DOI: 10.1021/Bi00441A014  0.687
1989 Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: Inhibition of DNA religation by etoposide Biochemistry. 28: 6157-6160. PMID 2551366 DOI: 10.1021/Bi00441A005  0.718
1989 Osheroff N. Biochemical basis for the interactions of type I and type II topoisomerases with DNA Pharmacology and Therapeutics. 41: 223-241. PMID 2540496 DOI: 10.1016/0163-7258(89)90108-3  0.676
1988 Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II in vivo and in total homogenates of Drosophila Kc cells. The role of casein kinase II. The Journal of Biological Chemistry. 263: 12653-60. PMID 2842338  0.343
1987 Osheroff N. Role of the divalent cation in topoisomerase II mediated reactions Biochemistry. 26: 6402-6406. PMID 2827726 DOI: 10.1021/Bi00394A015  0.546
1987 Osheroff N, Zechiedrich EL. Calcium-promoted DNA cleavage by eukaryotic topoisomerase II: Trapping the covalent enzyme-DNA complex in an active form Biochemistry. 26: 4303-4309. PMID 2822084 DOI: 10.1021/Bi00388A018  0.626
1986 Osheroff N. Eukaryotic topoisomerase II. Characterization of enzyme turnover Journal of Biological Chemistry. 261: 9944-9950. PMID 3015913  0.641
1985 Berrios M, Osheroff N, Fisher PA. In situ localization of DNA topoisomerase II, a major polypeptide component of the Drosophila nuclear matrix fraction Proceedings of the National Academy of Sciences of the United States of America. 82: 4142-4146. PMID 2987966 DOI: 10.1073/Pnas.82.12.4142  0.505
1985 Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proceedings of the National Academy of Sciences of the United States of America. 82: 3164-8. PMID 2987912 DOI: 10.1073/Pnas.82.10.3164  0.559
1985 Ackerman P, Glover CVC, Osheroff N. Modulation of DNA topoisomerase II activity by phosphorylation Federation Proceedings. 44.  0.535
1984 Osheroff N. Relaxation of supercoiled DNA by eukaryotic topoisomerase II Federation Proceedings. 43.  0.604
1983 Osheroff N, Shelton ER, Brutlag DL. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. The Journal of Biological Chemistry. 258: 9536-43. PMID 6308011  0.768
1983 Shelton ER, Osheroff N, Brutlag DL. DNA topoisomerase II from Drosophila melanogaster. Purification and physical characterization. The Journal of Biological Chemistry. 258: 9530-5. PMID 6308010  0.695
1979 Speck SH, Ferguson-Miller S, Osheroff N, Margoliash E. Definition of cytochrome c binding domains by chemical modification: kinetics of reaction with beef mitochondrial reductase and functional organization of the respiratory chain Proceedings of the National Academy of Sciences of the United States of America. 76: 155-159. PMID 218193 DOI: 10.1073/Pnas.76.1.155  0.307
Show low-probability matches.